1727 related articles for article (PubMed ID: 30613002)
1. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
3. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
[TBL] [Abstract][Full Text] [Related]
4. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
6. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
8. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.
Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P
J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
11. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
12. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
13. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
[TBL] [Abstract][Full Text] [Related]
14. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M;
Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220
[TBL] [Abstract][Full Text] [Related]
15. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
17. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination.
Ogawa E; Takayama K; Hiramine S; Hayashi T; Toyoda K
Aliment Pharmacol Ther; 2020 Sep; 52(5):866-876. PubMed ID: 32697871
[TBL] [Abstract][Full Text] [Related]
18. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]